Meditrina Pharmaceuticals, Inc. identifies and repurposes already marketed therapies and product candidates at advanced stages of development for new indications focused on improving women’s health disorders with unmet medical needs. The Company’s initial focus is in overlooked, therapeutic areas that affect millions of women each year. These areas include gynecologic and aromatase-meditated conditions such as endometrial thinning prior to hysteroscopic procedures including endometrial ablations, ectopic pregnancies, endometriosis and uterine fibroids.
Thomas Collett is CEO and co-founder.
In the news
Ann Arbor-based Meditrina Pharmaceuticals Inc. Thursday announced the approval of its second investigational new drug application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor. The drug is to be used in combination with estrogen and progestin for the treatment of endometriosis.
